Skip to main content


Media Coverage

FDA Finally Addresses Interchangeable Biosimilars

28 February 2017
In a bylined article, Litigation & Dispute Resolution partners Mark Mansour and Christopher Mikson and associate Emily Strunk (all Washington DC) discuss guidance the FDA has issued addressing the higher standard for interchangeability.

Related Information

  • Related People
    Christopher M. Mikson, MD
    T +1 202 263 3157
    Emily K. Strunk
    T +1 202 263 3404
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.